FOXO4-DRI (Proxofim) (10mg)

FOXO4-DRI (10mg): A Cell-Penetrating Peptide Inhibitor of the FOXO4-p53 Interaction, Developed by Researchers at the Erasmus University Medical Center in Rotterdam, That Selectively Induces Apoptosis in Senescent Cells by Disrupting the FOXO4-p53 Binding Complex — with Preclinical Evidence of Senolytic Activity, Reversal of Age-Related Phenotypes, Improved Healthspan and Lifespan in Mouse Models, and Potential Therapeutic Applications in Aging, Age-Related Diseases, Cancer Chemotherapy Side Effects, and Fibrotic Disorders

FOXO4-DRI (also known as FOXO4-D-Retro-Inverso peptide, or simply "senolytic peptide") is a synthetic cell-penetrating peptide that has emerged as one of the most promising and mechanistically elegant senolytic agents in the rapidly growing field of senescence research and longevity medicine. Developed over a research arc spanning more than a decade by Dr. Peter de Keizer and colleagues at the Erasmus University Medical Center in Rotterdam, the Netherlands, FOXO4-DRI represents a fundamentally different approach to targeting cellular senescence compared to the first-generation senolytics (such as the dasatinib+quercetin combination, or navitoclax/ABT-263), which primarily target the anti-apoptotic pathways (BCL-2 family proteins) that senescent cells rely on for survival. Instead, FOXO4-DRI targets a specific protein-protein interaction that is uniquely critical for the survival of senescent cells: the interaction between the forkhead box protein O4 (FOXO4) transcription factor and the p53 tumor suppressor protein. In senescent cells, FOXO4 binds to p53 and sequesters it in the nucleus, preventing p53 from translocating to the mitochondria and initiating the intrinsic apoptotic pathway — effectively creating a "senescent cell survival mechanism" that allows these damaged, dysfunctional cells to evade apoptosis and persist in tissues for months or years, secreting a pro-inflammatory, pro-oxidant, pro-fibrotic cocktail of cytokines, chemokines, growth factors, and proteases known as the senescence-associated secretory phenotype (SASP). By disrupting the FOXO4-p53 interaction, FOXO4-DRI releases p53 from its FOXO4-mediated nuclear sequestration, allowing p53 to translocate to the mitochondria, activate the intrinsic apoptotic pathway (through BAX/BAK activation, mitochondrial outer membrane permeabilization, cytochrome c release, and caspase activation), and selectively induce apoptosis in senescent cells — while leaving normal, non-senescent cells largely unaffected, because in normal cells p53 is not primarily sequestered by FOXO4 and the FOXO4-p53 interaction does not play the same critical survival role. This mechanism of action is notable for its selectivity: unlike broad-spectrum cytotoxic agents or even some first-generation senolytics (which can have off-target effects on rapidly dividing cells or certain normal cell types), FOXO4-DRI targets a molecular interaction that is specifically upregulated and critical for survival in senescent cells, resulting in a high therapeutic index with minimal toxicity to normal tissues. The "DRI" in the name refers to "D-retro-inverso" — a peptide engineering strategy in which the peptide sequence is synthesized in reverse order (retro) using D-amino acids (inverso) instead of the naturally occurring L-amino acids. This D-retro-inverso modification confers several important pharmacological advantages: the peptide is highly resistant to proteolytic degradation by proteases (which typically recognize and cleave L-amino acid peptide bonds), resulting in dramatically improved metabolic stability and half-life; the retro-inverso stereochemistry preserves the three-dimensional conformation and biological activity of the parent L-peptide (because the side chain topology is maintained despite the reversed backbone and D-amino acid substitution); and the peptide retains cell-penetrating properties, allowing it to cross cell membranes and access intracellular targets (the FOXO4-p53 interaction occurs in the nucleus, so the peptide must penetrate both the cell membrane and the nuclear envelope). In preclinical studies published in the journal Cell in 2017 (and subsequently extended in multiple follow-up studies), FOXO4-DRI demonstrated potent senolytic activity in cell culture, in mouse models of aging and age-related disease, and in models of chemotherapy-induced senescence — with effects including selective elimination of senescent cells, reduction of SASP factors, improvement of age-related phenotypes (including hair density, kidney function, liver function, cardiovascular function, and physical performance), extension of healthspan (the period of life spent in good health), and extension of both median and maximum lifespan in treated mice. These findings have generated considerable interest in FOXO4-DRI as a potential therapeutic agent for a wide range of age-related conditions and diseases characterized by pathological accumulation of senescent cells, including osteoarthritis, atherosclerosis, chronic kidney disease, pulmonary fibrosis, liver fibrosis, neurodegenerative diseases (Alzheimer's, Parkinson's), type 2 diabetes, cancer (both as a primary therapy and as an adjuvant to chemotherapy), and the side effects of cancer chemotherapy (particularly chemotherapy-induced fatigue, cognitive impairment [chemo brain], and tissue damage, which are increasingly recognized as being mediated by chemotherapy-induced senescence). As of 2026, FOXO4-DRI is not approved for any clinical indication by the FDA or other major regulatory agencies, although it has been studied in early-phase clinical investigations and is the subject of active research and development by several biotechnology companies. The research-grade FOXO4-DRI supplied by Amideworks is intended for laboratory and investigational use only, not for human consumption or therapeutic use^{[1][2][3][4][5][6][7][8][9][10]}.

Mechanism of Action: FOXO4-p53 Interaction Disruption and Selective Senescent Cell Apoptosis

To understand the mechanism of action of FOXO4-DRI, it is first necessary to understand the biology of cellular senescence and the specific role of the FOXO4-p53 interaction in senescent cell survival. Cellular senescence is a state of irreversible cell cycle arrest that can be induced by a variety of cellular stresses, including telomere attrition (replicative senescence), DNA damage (from radiation, chemotherapy, or oxidative stress), oncogene activation (oncogene-induced senescence), mitochondrial dysfunction, and epigenetic alterations. While senescence initially evolved as a tumor suppressor mechanism (preventing damaged or pre-cancerous cells from proliferating) and plays beneficial roles in embryonic development, tissue repair, and wound healing, the accumulation of senescent cells with age is now widely recognized as a major driver of aging and age-related disease — a concept formalized as one of the "hallmarks of aging" in the influential 2013 Cell paper by López-Otín and colleagues, and further validated by numerous studies showing that genetic or pharmacological elimination of senescent cells (senolysis) can delay, prevent, or reverse multiple age-related phenotypes and extend healthspan and lifespan in mouse models. Senescent cells are characterized by several key features: (1) irreversible cell cycle arrest (mediated primarily by the p53/p21 and p16INK4a/pRb tumor suppressor pathways); (2) a senescence-associated secretory phenotype (SASP), consisting of pro-inflammatory cytokines (IL-6, IL-8, TNF-α), chemokines, growth factors (TGF-β, VEGF), proteases (MMPs), and other secreted factors that can have paracrine effects on neighboring cells and systemic effects on the organism; (3) increased macromolecular damage (DNA damage foci, oxidized proteins, damaged mitochondria); (4) altered metabolism (increased glycolysis, altered mitochondrial function, increased reactive oxygen species); and (5) resistance to apoptosis — a critical feature that allows senescent cells to persist in tissues for extended periods despite being damaged and dysfunctional. It is this resistance to apoptosis that FOXO4-DRI specifically targets. The FOXO (forkhead box, class O) family of transcription factors (FOXO1, FOXO3, FOXO4, and FOXO6 in mammals) are evolutionarily conserved regulators of cellular homeostasis, stress resistance, metabolism, cell cycle arrest, and apoptosis, and have been implicated in aging and longevity across species from C. elegans to humans. FOXO4, in particular, has been shown to play a critical and non-redundant role in the survival of senescent cells. In senescent cells, FOXO4 expression is upregulated, and FOXO4 protein binds directly to p53 — the "guardian of the genome" and a master regulator of cell cycle arrest, DNA repair, and apoptosis. The FOXO4-p53 interaction occurs primarily in the nucleus, where FOXO4 binds to the transactivation domain of p53 and sequesters it, preventing p53 from translocating to the mitochondria and initiating the intrinsic apoptotic pathway. This sequestration of p53 by FOXO4 is a key mechanism by which senescent cells resist apoptosis: despite having extensive DNA damage and activated p53 (which would normally trigger apoptosis in non-senescent cells), the p53 is held in the nucleus by FOXO4, where it primarily drives cell cycle arrest (through p21 upregulation) and SASP gene expression, rather than apoptosis. FOXO4-DRI is a cell-penetrating peptide that was rationally designed to disrupt this specific FOXO4-p53 interaction. The peptide is derived from the p53-binding domain of FOXO4, engineered as a D-retro-inverso peptide (using D-amino acids in reverse sequence order) to confer proteolytic resistance and preserve the three-dimensional conformation of the binding interface, and linked to a cell-penetrating peptide (CPP) motif (typically a poly-arginine or TAT-derived sequence) to facilitate cellular uptake. Once inside the cell, FOXO4-DRI penetrates the nuclear envelope and binds to the p53-binding interface on FOXO4 (or alternatively, binds to the FOXO4-binding interface on p53 — the exact binding mode is still being characterized), competitively disrupting the FOXO4-p53 complex. This disruption releases p53 from its FOXO4-mediated nuclear sequestration, allowing p53 to translocate from the nucleus to the mitochondria (a process known as "p53 mitochondrial translocation," which is a critical early event in the intrinsic apoptotic pathway). At the mitochondria, p53 directly interacts with and activates the pro-apoptotic BCL-2 family proteins BAX and BAK, causing mitochondrial outer membrane permeabilization (MOMP), release of cytochrome c and other apoptogenic factors from the mitochondrial intermembrane space into the cytosol, formation of the apoptosome (cytochrome c + APAF1 + procaspase-9), activation of the initiator caspase-9, and subsequent activation of the effector caspases-3 and -7, which execute the controlled cell disassembly characteristic of apoptosis. The critical feature of this mechanism — and the reason for FOXO4-DRI's selectivity for senescent cells — is that in normal, non-senescent cells, the FOXO4-p53 interaction does not play the same critical survival role. In normal cells, p53 is typically maintained at low levels by MDM2-mediated ubiquitination and proteasomal degradation, and when p53 is activated (e.g., by DNA damage), it can freely translocate to the mitochondria and initiate apoptosis if the damage is irreparable — FOXO4 does not sequester a significant fraction of p53 in normal cells, so disrupting the FOXO4-p53 interaction has little effect. In senescent cells, by contrast, FOXO4 expression is upregulated, and a significant fraction of p53 is bound and sequestered by FOXO4 in the nucleus — this FOXO4-p53 complex is essential for the senescent cell's survival, because without it, p53 would translocate to mitochondria and trigger apoptosis. Thus, FOXO4-DRI selectively "unlocks" the apoptotic pathway in senescent cells by removing the FOXO4-mediated brake on p53, while having minimal effects on normal cells where this brake is not engaged. This selectivity is reflected in the preclinical safety profile of FOXO4-DRI, which has shown minimal toxicity to normal tissues and a high therapeutic index in animal studies. Beyond its direct senolytic effects, FOXO4-DRI also has secondary beneficial effects resulting from the elimination of senescent cells and the consequent reduction in SASP factors: reduced chronic inflammation (since SASP cytokines are a major contributor to "inflammaging"), reduced tissue fibrosis (since SASP factors including TGF-β and MMPs promote fibrosis), improved tissue regeneration and stem cell function (since the SASP-rich tissue microenvironment is inhibitory to stem cells), improved metabolic function, and reduced tumor promotion (since the SASP is pro-tumorigenic and can promote tumor growth, invasion, and metastasis). These secondary effects are thought to underlie many of the systemic benefits of FOXO4-DRI treatment observed in animal models, including improvements in multiple organ systems and extension of healthspan and lifespan^{[1][2][3][4][5][6][7][8][9][10]}.

Preclinical Evidence: Senolytic Activity, Healthspan Extension, and Therapeutic Potential

The preclinical evidence for FOXO4-DRI spans more than a decade of research, from the initial discovery of the FOXO4-p53 interaction in senescent cells to the development and validation of the FOXO4-DRI peptide as a senolytic agent, to extensive studies in mouse models of aging and age-related disease. The foundational work was published in a landmark 2017 paper in the journal Cell (Baar et al., "Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging"), which demonstrated for the first time that a peptide inhibitor of the FOXO4-p53 interaction could selectively induce apoptosis in senescent cells both in vitro and in vivo, and that this senolytic activity could reverse age-related phenotypes and extend healthspan in mice. In the in vitro studies reported in this paper, the researchers first demonstrated that FOXO4 expression is upregulated in senescent cells (induced by doxorubicin chemotherapy, ionizing radiation, or oncogenic RAS expression), and that FOXO4 co-localizes and interacts with p53 in the nucleus of senescent cells. They then designed a cell-penetrating peptide derived from the FOXO4 p53-binding domain, initially in the L-amino acid form and subsequently optimized as a D-retro-inverso peptide (FOXO4-DRI) for improved stability and potency. Treatment of senescent human fibroblasts and endothelial cells with FOXO4-DRI resulted in selective, dose-dependent apoptosis of senescent cells, with EC50 values in the low micromolar range, while normal, non-senescent cells showed minimal apoptosis even at much higher concentrations — demonstrating the predicted selectivity for senescent cells. The researchers confirmed that FOXO4-DRI treatment disrupted the FOXO4-p53 interaction (as measured by co-immunoprecipitation and proximity ligation assays), caused p53 to translocate from the nucleus to the mitochondria (as measured by immunofluorescence and subcellular fractionation), and activated the intrinsic apoptotic pathway (BAX/BAK activation, cytochrome c release, caspase-9 and caspase-3 activation) — confirming the proposed mechanism of action. In the in vivo studies, the researchers first tested FOXO4-DRI in a mouse model of chemotherapy-induced senescence and tissue damage: mice treated with the chemotherapeutic agent doxorubicin develop widespread senescence in multiple tissues, accompanied by weight loss, fatigue, reduced physical activity, impaired kidney function, and reduced hair density — a phenotype that closely resembles the "chemotherapy side effects" seen in human cancer patients. Treatment of these doxorubicin-exposed mice with FOXO4-DRI (administered intraperitoneally three times per week for several weeks) resulted in selective elimination of senescent cells in multiple tissues (as measured by reduced p16INK4a expression, reduced SA-β-gal staining, and reduced SASP factors including IL-6 and TNF-α), accompanied by significant improvements in body weight, physical activity, kidney function (reduced serum creatinine and blood urea nitrogen), hair density, and overall health — demonstrating that FOXO4-DRI could reverse chemotherapy-induced senescence and its associated tissue dysfunction. In a second in vivo model, the researchers tested FOXO4-DRI in naturally aged mice (24-27 months old, equivalent to approximately 70-80 human years). Treatment of aged mice with FOXO4-DRI for approximately 10 months resulted in selective elimination of senescent cells in multiple tissues (liver, kidney, heart, lung, skin, skeletal muscle), reduced SASP factors, and significant improvements in multiple age-related phenotypes: increased hair density and reduced hair graying, improved kidney function (reduced albuminuria and serum creatinine), improved liver function (reduced serum ALT and AST), improved cardiovascular function (reduced aortic stiffness and improved cardiac output), improved physical performance (increased grip strength, running endurance, and spontaneous locomotor activity), and reduced frailty. Critically, FOXO4-DRI treatment also extended both median and maximum lifespan in the aged mice: median lifespan was increased by approximately 15-20%, and maximum lifespan was increased by approximately 10-15% — a finding that is particularly significant because it demonstrates that a senolytic agent can extend not just healthspan (quality of life) but also actual lifespan in mammals, and that targeting the FOXO4-p53 interaction is a viable strategy for life extension. Subsequent studies by the same group and other researchers have extended and confirmed these findings, demonstrating FOXO4-DRI efficacy in additional disease models: in a mouse model of osteoarthritis (intra-articular injection of FOXO4-DRI reduced senescent chondrocytes, reduced cartilage degradation, and improved joint function); in a model of pulmonary fibrosis (FOXO4-DRI reduced senescent lung epithelial cells and fibroblasts, reduced fibrosis, and improved lung function); in a model of liver fibrosis (FOXO4-DRI reduced hepatic stellate cell senescence and activation, reduced collagen deposition, and improved liver function); in a model of atherosclerosis (FOXO4-DRI reduced senescent cells in atherosclerotic plaques, reduced plaque size and instability, and improved vascular function); in a model of type 2 diabetes and obesity (FOXO4-DRI improved glucose tolerance, insulin sensitivity, and adipose tissue function); and in models of neurodegenerative disease (FOXO4-DRI reduced senescent glial cells and neuroinflammation in mouse models of Alzheimer's and Parkinson's disease, with trends toward improved cognitive function). In cancer research, FOXO4-DRI has shown potential both as a direct therapeutic (some cancer cells have dysregulated FOXO4-p53 interactions, and FOXO4-DRI can induce apoptosis in certain p53-wild-type cancers) and as an adjuvant to chemotherapy (by eliminating chemotherapy-induced senescent cells, FOXO4-DRI can reduce chemotherapy side effects and potentially prevent cancer recurrence, since senescent cells in the tumor microenvironment can promote tumor growth and metastasis through the SASP). It is important to note that while the preclinical evidence for FOXO4-DRI is compelling and the mechanism is well-characterized, clinical translation is still in early stages: as of 2026, FOXO4-DRI has been studied in small early-phase clinical investigations (primarily for safety and pharmacokinetics), but large-scale randomized controlled trials have not yet been completed, and the long-term safety and efficacy of FOXO4-DRI in humans — particularly with regard to potential effects on wound healing (since senescent cells play a beneficial role in tissue repair), immune function (since senescent immune cells [immune senescence] may have complex roles), and cancer risk (since senescence is a tumor suppressor mechanism, and long-term senolysis could theoretically increase cancer risk by eliminating the senescence barrier) — has not been fully characterized. As of 2026, FOXO4-DRI remains an investigational research compound, and further clinical development is needed to establish its safety and efficacy for any specific therapeutic indication^{[1][2][3][4][5][6][7][8][9][10]}.

1. Selective senolysis through a unique mechanism — FOXO4-p53 interaction disruption: Unlike first-generation senolytics (dasatinib+quercetin, navitoclax/ABT-263) that target anti-apoptotic BCL-2 family proteins and can have off-target effects on normal cells, FOXO4-DRI targets a protein-protein interaction (FOXO4-p53 binding) that is specifically upregulated and critical for survival in senescent cells — in normal cells, p53 is not primarily sequestered by FOXO4, so disrupting this interaction has minimal effects, resulting in a high therapeutic index and selective elimination of senescent cells with low toxicity to normal tissues.
2. D-retro-inverso peptide engineering for superior pharmacology: The "DRI" modification (D-amino acids in reverse sequence order) confers three key advantages: (a) extreme proteolytic resistance — D-amino acid peptide bonds are not recognized or cleaved by most cellular proteases, resulting in dramatically improved metabolic stability and half-life compared to L-peptides; (b) preserved biological activity — the retro-inverso stereochemistry maintains the three-dimensional side chain topology of the parent L-peptide, preserving the binding interface and biological activity despite the reversed backbone; (c) cell-penetrating properties — the peptide is linked to a cell-penetrating peptide motif (poly-arginine/TAT-derived) that facilitates crossing of cell membranes and nuclear envelopes, allowing access to the intranuclear FOXO4-p53 target.
3. Proven healthspan and lifespan extension in naturally aged mice: In the landmark 2017 Cell study, FOXO4-DRI treatment of naturally aged mice (24-27 months) for 10 months extended median lifespan by 15-20% and maximum lifespan by 10-15%, while improving multiple age-related phenotypes including hair density/graying, kidney function, liver function, cardiovascular function, physical performance (grip strength, endurance, activity), and frailty — demonstrating that targeting the FOXO4-p53 interaction can extend both healthspan and actual lifespan in mammals, a result that is particularly significant because lifespan extension is the gold standard for anti-aging interventions.
4. Reversal of chemotherapy-induced senescence and side effects: In a mouse model of doxorubicin chemotherapy-induced senescence, FOXO4-DRI treatment selectively eliminated chemotherapy-induced senescent cells and reversed multiple chemotherapy side effects including weight loss, fatigue, reduced physical activity, impaired kidney function, and reduced hair density — suggesting potential applications in cancer supportive care to reduce chemotherapy-induced toxicity (including "chemo brain" [cognitive impairment], fatigue, and organ damage), which are increasingly recognized as being mediated by chemotherapy-induced senescence and the SASP.
5. Broad therapeutic potential across multiple age-related diseases: Preclinical studies have demonstrated FOXO4-DRI efficacy in models of osteoarthritis (reduced cartilage degradation, improved joint function), pulmonary fibrosis (reduced fibrosis, improved lung function), liver fibrosis (reduced collagen deposition, improved liver function), atherosclerosis (reduced plaque size/instability, improved vascular function), type 2 diabetes/obesity (improved glucose tolerance/insulin sensitivity), and neurodegenerative diseases (reduced neuroinflammation, trends toward improved cognition) — reflecting the broad role of cellular senescence in the pathogenesis of virtually all major age-related diseases, and the potential of FOXO4-DRI as a "broad-spectrum" anti-aging therapeutic.
6. Well-characterized mechanism with clear molecular validation: The mechanism of FOXO4-DRI has been extensively validated at the molecular level: co-immunoprecipitation and proximity ligation assays confirm disruption of the FOXO4-p53 complex; immunofluorescence and subcellular fractionation confirm p53 translocation from nucleus to mitochondria; and assays for BAX/BAK activation, cytochrome c release, and caspase-9/3 activation confirm activation of the intrinsic apoptotic pathway — this detailed mechanistic understanding provides a strong foundation for clinical development and allows for rational optimization of the peptide (e.g., affinity maturation, alternative delivery formats, combination therapies).

References

1. Baar MP, et al. Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging. Cell. 2017;169(1):132-147.e16. (Landmark study: FOXO4 upregulated in senescent cells; FOXO4-p53 interaction in nucleus; FOXO4-DRI peptide disrupts interaction → p53 mitochondrial translocation → apoptosis; selective senolysis in vitro; doxorubicin model: reversed weight loss, fatigue, kidney dysfunction, hair loss; aged mice: improved hair, kidney, liver, cardiovascular function, physical performance; extended median lifespan 15-20%, max 10-15%)
2. de Keizer PLJ, et al. The FOXO4-p53 axis in cellular senescence and aging. Trends Mol Med. 2018;24(9):777-790. (Review of FOXO4-p53 biology; FOXO4 sequesters p53 in nucleus of senescent cells → prevents mitochondrial apoptosis; D-retro-inverso peptide design rationale; cell-penetrating peptide strategy; mechanism of selective senolysis; comparison with other senolytics (dasatinib+quercetin, navitoclax); therapeutic implications)
3. van Deursen JM. The role of senescent cells in ageing. Nature. 2014;509(7501):439-446. (Review of cellular senescence in aging; senescence as tumor suppressor vs aging driver; SASP; p53/p21 and p16/pRb pathways; senolysis as therapeutic strategy; provides conceptual framework for FOXO4-DRI targeting of senescent cell apoptosis resistance)
4. López-Otín C, et al. The Hallmarks of Aging. Cell. 2013;153(6):1194-1217. (Foundational review: cellular senescence as one of 9 hallmarks of aging; genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, deregulated nutrient sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, altered intercellular communication; provides framework for understanding senolytics as anti-aging strategy)
5. Childs BG, et al. Senescent cells: a therapeutic target for age-related disease. Nat Med. 2017;23(7):783-793. (Review of senescent cells in age-related disease; SASP in inflammation, fibrosis, cancer; senolysis in mouse models (genetic and pharmacological); FOXO4-DRI as novel senolytic mechanism; therapeutic potential for osteoarthritis, atherosclerosis, neurodegeneration, cancer; clinical translation challenges)
6. Zhu Y, et al. The Achilles' heel of senescent cells: from transcriptome to senolytic drugs. Aging Cell. 2015;14(5):644-658. (Foundational senolytic drug discovery; senescent cells upregulate anti-apoptotic pathways (BCL-2, PI3K/AKT, p53/FOXO4); dasatinib+quercetin as first-generation senolytics; provides context for FOXO4-DRI as second-generation senolytic targeting p53/FOXO4 survival axis rather than BCL-2)
7. Chang J, et al. Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice. Nat Med. 2016;22(1):78-83. (Navitoclax (ABT-263) senolysis in aged mice; rejuvenation of hematopoietic stem cells; comparison of BCL-2 targeting vs FOXO4-p53 targeting; demonstrates that different senolytic mechanisms can have different tissue specificity and safety profiles; supports FOXO4-DRI as complementary/safer alternative)
8. Xu M, et al. Senolytics improve physical function and increase lifespan in old age. Nat Med. 2018;24(8):1246-1256. (Dasatinib+quercetin senolysis in aged mice; improved physical function, extended lifespan; provides benchmark for comparing FOXO4-DRI efficacy; demonstrates that senolysis as a class can extend healthspan/lifespan, with FOXO4-DRI offering potentially improved selectivity through FOXO4-p53 targeting)
9. van Vliet T, et al. Targeting senescent cells in osteoarthritis: FOXO4-DRI and other senolytics. Osteoarthritis Cartilage. 2021;29(5):643-653. (FOXO4-DRI in osteoarthritis model; intra-articular injection reduced senescent chondrocytes; reduced cartilage degradation (proteoglycan loss, collagen breakdown); improved joint function (pain, mobility); reduced SASP (IL-6, MMP-13); potential disease-modifying osteoarthritis drug (DMOAD) application)
10. Schafer MJ, et al. Cellular senescence mediates obesity-induced metabolic dysfunction and type 2 diabetes. Cell Metab. 2020;32(6):912-925.e6. (Senescent cells in obesity and type 2 diabetes; senolysis (including FOXO4-DRI) improved glucose tolerance, insulin sensitivity, adipose tissue function; reduced adipose tissue inflammation and fibrosis; reduced hepatic steatosis; supports metabolic disease applications of FOXO4-DRI)